Literature DB >> 3002660

Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.

W H Lee, M Packer.   

Abstract

Although past reports have identified a variety of prognostic factors in patients with severe chronic heart failure, previous studies have not evaluated the interaction of prognostic variables and drug treatment. We analyzed the association of 30 clinical, hemodynamic, and biochemical variables with survival in 203 consecutive patients with severe heart failure; all variables were assessed just before initiation of treatment with a variety of vasodilator drugs, and all patients were subsequently followed for 6 to 94 months. By regression analysis, pretreatment serum sodium concentration was the most powerful predictor of cardiovascular mortality, with hyponatremic patients having a substantially shorter median survival than did patients with a normal serum sodium concentration (164 vs 373 days, p = .006). The unfavorable prognosis for hyponatremic patients appeared to be related to the marked elevation of plasma renin activity that we noted in these individuals (10.0 +/- 2.0 ng/ml/hr), since hyponatremic patients fared significantly better when treated with angiotensin converting-enzyme inhibitors than when treated with vasodilator drugs that did not interfere with angiotensin II biosynthesis (median survival 232 vs 108 days, p = .003). In contrast, there was no selective benefit of converting-enzyme inhibition on the survival of patients with a normal serum sodium concentration, in whom plasma renin activity was low (1.9 +/- 0.3 ng/ml/hr). This interaction between serum sodium concentration, drug treatment, and long-term outcome suggests that the renin-angiotensin system may exert a deleterious effect on the survival of some patients with chronic heart failure, which can be antagonized by converting enzyme inhibition, and provides a clinical counterpart for the similar prognostic role that has been postulated for angiotensin II in experimental preparations of heart failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3002660     DOI: 10.1161/01.cir.73.2.257

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  70 in total

Review 1.  The need for palliative care in the management of heart failure.

Authors:  Christopher Ward
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 2.  Water retention and aquaporins in heart failure, liver disease and pregnancy.

Authors:  R W Schrier; M A Cadnapaphornchai; M Ohara
Journal:  J R Soc Med       Date:  2001-06       Impact factor: 5.344

3.  Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects.

Authors:  Beth Wilmot; V Saroja Voruganti; Yen-Pei C Chang; Yi Fu; Zhan Chen; Herman A Taylor; James G Wilson; Teresa Gipson; Vallabh O Shah; Jason G Umans; Michael F Flessner; Robert Hitzemann; Alan R Shuldiner; Anthony G Comuzzie; Shannon McWeeney; Philip G Zager; Jean W Maccluer; Shelley A Cole; David M Cohen
Journal:  Physiol Genomics       Date:  2011-12-20       Impact factor: 3.107

4.  Low serum sodium as a poor prognostic indicator for mortality in congestive heart failure patients.

Authors:  Andrew DeWolfe; Barbara Lopez; Lee M Arcement; Kathy Hebert
Journal:  Clin Cardiol       Date:  2010-11-22       Impact factor: 2.882

5.  Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure.

Authors:  J D Newton; I B Squire
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 6.  Predicting survival in heart failure.

Authors:  Viorel G Florea; Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

7.  [Hyponatremia].

Authors:  Alexandra Scholze; Martin Tepel
Journal:  Med Klin (Munich)       Date:  2009-02-15

Review 8.  Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?

Authors:  Gregory Valania; Manmeet Singh; Mara T Slawsky
Journal:  Curr Heart Fail Rep       Date:  2011-09

9.  Creation of a hyponatremia registry supported by an industry-derived quality control methodology.

Authors:  Giunta D; Fuentes N; Pazo V; Posadas-Martínez M L; Michellangelo H; Waisman G; González Bernaldo De Quirós F
Journal:  Appl Clin Inform       Date:  2010-03-02       Impact factor: 2.342

10.  Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy.

Authors:  K P Anderson; R Walker; P Urie; P R Ershler; R L Lux; S V Karwandee
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.